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POSTGRADUATE MEDICINE 
Drs. M. G. Kelly, A. G. Shattock, G. D. Doyle and J.F. Fielding* write on the detection and 
treatment of drug abuse associated with liver disease which is becoming rampant among 
adolescents 
Drug induced liver disease 
INTRAVENOUS drug abuse is an abuse of adolescents with morbidity and even mortality at that age. In 
contradistinction the morbidity and mortality associated with the abuse of nicotine and alcohol mainly 
affect those of middle age. Thus the importance of drug abuse associated morbidity and mortality is its 
impact on those who have not yet experienced adulthood. 
 The size of the problem is ever increasing. In the month of September this year no fewer than 56 
new heroin abusers presented to the Drug Advisory and Treatment Centre. 
Drug Abuse associated Liver Disease 
 The size of the problem: With the rapid growth in the number of intravenous drug abusers comes a 
corresponding increase in the risk of liver disease amongst such abusers. While it is impossible to 
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quantitale the risk on a long term basis there is evidence to suggest that some six tenths of the abusers will 
develop chronic active hepatitis. 
 This does not include the increased numbers of close contacts who will also be at risk. Moreover, 
the calculated risk only applies to those abusers attending the National Drug Advisory and Treatment 
Centre and may just represent the visible portion (orevenjust the top) of the iceberg as far as the country is 
concerned. 
 Antiviral therapy and vaccinations (against hepatitis B virus and when developed against Non A 
Non B viruses) may alter these risks but will be too late to affect the current problem. If the number of 
new abusers were but to continue at its present rate (and current evidence is that it is still increasing) then 
one can expect over 400 cases of chronic liver disease per year of which some 135 would have chronic 
active hepatitis. 
 Clearly the size of the problem calls out for urgent action to assist in the prevention, detection and 
treatment of this appalling psychosocial problem. Whilst there have been many pious utterances of such 
assistance little help has been forthcoming for the management of intravenous drug abuse associated liver 
disease. 
 
 There is not even an isolation area attached to the National Drug Advisory and Treatment centre 
for the global management of these patients despite numerous requests for same. Thus health care 
personnel and close contacts of the patients are put at unnecessary risk of becoming infected by HBV and 
other viruses. The Department of Health which has consistently limited to provide this isolation area over 
(he past few years must accept responsibility for such increase risk. 
 The Diagnosis of Drug Abuse associated Liver Disease: Often this has to be done in conjunction 
with the psychiatric management of the patient as continuing psychiatric supervision and isolation may be 
essential to abuse withdrawal. Moreover, irrespective of the biochemical parameters the only way of 
knowing the state of the abuser’s liver is to perform at least one liver biopsy. Only then may one decide if 
the liver disease is such as to warrant treatment in its own right. 
 The histological diagnoses vary from normal (very rare), through minor changes, acute hepatitis, 
chronic persistent hepatitis, chronic active hepatitis to chronic active hepatitis with cirrhosis. Current 
evidence would suggest that those with HBV associated chronic active hepatitis are at increased risk of 
long term development of hepatocellular carcinoma. 
Treatment of Drug Abuse Associated Liver Disease: 
 Treatments currently being investigated include the use of an antiviral agent in an effort to lessen 
the risk of acute hepatitis developing into 
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chronic hepatitis and the use of an anti-inflammatory/immunosuppressive agent in an effort to lessen the 
risk of progression of chronic active hepatitis to chronic active hepatitis with cirrhosis. 
 The virology of Hepatitis and its serological diagnosis: At least four common types of viruses 
causing hepatitis are recognised at the present time: Hepatitis A virus, causing “infectious hepatitis”, 
Hepatitis B virus, causing “serum hepatitis” and the more recently recognised Non A, Non B hepatitis. 
There is considerable evidence that there are at least two forms of Non A Non B hepatitis with different 
incubation periods. Hepatitis A and B can now be distinguished by serological tests but laboratory tests 
for Non A Non B hepatitis are still in the research stage. 
 Although drug abusers just as other members may develop hepatitis. As such infection does not 
contribute to chronic liver disease and hence the virology of hepatitis A, it will not be discussed in detail 
in this paper. Suffice to say that one needs to exclude the presence of hepatitis A as a cause of acute 
hepatitis in those patients who are negative for hepatitis B markers, to enable one to attribute the hepatitis 
to one of the Non A Non B viruses. 
 Hepatitis B: The discovery of the association of the “Australian antigen” with hepatitis B in 196S 
led to the current explosion of research into viral hepatitis. This antigen, now known as hepatitis B 
 
surface antigen (HBsAg), is present in the serum of patients during the late incubation period and the 
acute phase of serum hepatitis and is usually cleared during convalescence in a variable period of time. 
 Also appearing in the serum before the onset of symptoms and biochemical changes are the DNA 
polymerase and the “e” antigen, both associated with the hepatitis B virus and proven markers of 
infectivity. These markers arc normally “e”antigen beyond 10 weeks is ominous. Simultaneously with or 
shortly after the disappearance of the “e” antigen, antibody to the “e” antigen appears and is a marker for 
greatly reduced or non-infectivity, although this is not absolute. 
 The seroconversion from hepatitis B “e” antigen to anti-HBe within 10 weeks of onset (usually) 
earlier normally heralds complete recovery. Antibody to core of the virus (anti-HBc) is found from the 
onset of symptoms and persists, usually for years. 
 Finally, often considerably later than the clearance of HBsAg, the antibody to the surface antigen 
(anti-HBs) appears. Anti-HBs is the antibody which confers immunity and is the antibody which is 
elicited following vaccination. 
 How do all these different antigens of he pat it is B relate to each other? The virus, often called the 
Dane panicle after its discoverer Dr. David Dane of the Middlesex Hospital, is unusual, many would say 
extraordinary. 
 It consists of a “core” structure containing DNA, part of which is only single-stranded, plus core 
antigen and DNA polymerase. One of the components of the core antigen complex is the “e” antigen. 
 The core structure is surrounded by a layer of the surface antigen acting as a protective coat. 
However during multiplication of the virus in the hepatocytes large quantities of the surface antigen and 
“e” antigen are produced surplus to the requirements for just building new virus particles. 
 This surplus surface antigen and “e” antigen appear in the blood. However the “e” antigen is only 
produced during the replication of the virus itself, whereas the surface antigen is often continued to be 
produced even in the absence of viral replication. 
 The mechanisms and reason for the production of surplus HBsAg and “e” antigen are still unknown 
although the advantage to the virus of having surplus proteins to “mop up” antibodies to surface antigen 
are obvious. The surplus surface antigen appears as very numerous small particles approximately half the 
size of the virus and also as tubules of various lengths. It is the small particles of surface antigen that are 
isolated, purified and inactivated and used in the manufacture of the currently available vaccine. 
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antigens are responsible for the epidemiologically useful subtypes of HbsAg, but there are no known 
differences in virulence between subtypes. 
 
 South antibody and cell-mediated immunity are involved in clearing the virus and antigens from 
the system. Chronic hepatitis B with continuing HgsAg antigenaemia may develop in some cases, 
possibly due to the absence of certain antibodies, but the exact mechanism is unknown. 
 Chronic carriage of HBsAg may persist long after liver damage has resolved and biochemistry 
returned to normal. Such cases are relatively common and mainly non-infectious and often only 
discovered because of blood donation. 
 Others may have progressive liver disease due to abnormal cell mediated immune reactions, and 
may eventually progress to cirrhosis. Carriers are more common among males and more likely to occur if 
the infection is acquired during birth or in childhood. 
 It is estimated from surveys carried out world wide that there are over 175 million hepatitis B 
carriers in the world, the incidence varying from less than one per thousand in the western world to more 
than 10% in tropical 
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countries and the Far East. In • Ireland* the carrier rate is approximately one per 2000 persons. 
 Usefulness of tests for monitoring hepatitis B: One of the first uses of tests for HBsAg was, and 
stilt is, for screening blood donors. This has eliminated most cases of post-transfusion hepatitis B 
although, because t-o lest is sufficiently sensitive to detect all donors with the lowest level of circulating 
virus, a few cases caused by hepatitis B do still occur. 
 The most sensitive tests for its detection are radio-immuno - assay (EIA, ELISA) and some types of 
passive haemagglutination. These tests are employed by blood banks world wide for their donor 
screening. 
 Extra sensitive versions of these tests, together with a battery of tests for other markers, are 
available at the Virus Reference Laboratory, U.C.D., for the serological diagnosis, confirmation and for 
monitoring the recovery of patients with hepatitis B infection. (It is noteworthy that Ireland has made a 
valuable contribution to diagnostic hepatitis technology in that staff at the Virus Reference Laboratory at 
U.C.D. were among the first to work on the “e” antigen and this led to the development of a sensitive 
enzyme-immuno-assay for the detection of the prognostically significant “e” antigen and antibody). 
 Patients’ sera found positive for hepatitis B surface antigen are automatically tested for the “e” 
antigen and antibody, so that specific requests for the latter are unnecessary. Tests with hepatitis B and 
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to the HBsAg test, although the economics of this operation would appear to make it unjustified at 
present. IgM specific anti-HBc tests have recently been developed in some laboratories and will become 
useful for diagnosis during the “window period” when the HBsAg has cleared but anti-HBs may not be 
detectable. 
 Prophylaxis of Hepatitis B: Two approaches are now possible in the prbphylaxis of hepatitis B: 
Hepatitis B specific hyperimmune gamma-globuin (HBIG) and vaccination. The former is a preparation 
made from anti-HBs rich plasma and is very useful in the prevention (or modification) of hepatitis B in 
needlestick and other accidental exposure and in babies born to mothers in the acute stage of hepatitis B; 
To be of maximum effect in the latter it has been shown essential to administer HBIG has passed all 
clinical trials, where it was found safe, very effective and without side-effects. It has been used in over 
13,000 persons in “high risk” groups. These include renal dialysis patients and staff, homosexuals, drug 
addicts, laboratory and some categories of hospital staff, and others. For the first time ever a vaccine has 
been produced before the virus was propagated de novo in tissue culture! 
 Non-A, Non-B Viral Hepatitis: At present the definition of this type of hepatitis is hepatitis of 
viral origin where hepatitis A, B, cytomegalovirus and Epstein-Barr virus infection have been excluded. 
Leptospirosis and toxoplasmosis may also need to be tested for. 
 There are at least two types of Non-A, Non-B viruses based on incubation periods and chimpanzee 
transmission experiments. Further more an ‘epidemic’ type has been described in several areas, 
principally in India. It is the commonest type of post-transfusion hepatitis in the United Slates and causes 
 
a sizeable proportion of sporadic acute hepatitis in many, if not most countries for which data are 
available. 
 In Ireland this figure is estimated from data published by A.G.S. to be 50%. However there are 
many sub-clinical causes; other characteristics useful in its study are the frequent appearance of multiple 
peaks of the transaminases and unique histological findings in chimpanzee studies. 
 It is increasingly clear that the DNA polymerase and the “e” antigen, both associated with the 
hepatitis B virus and proven markers of infectivity. These markers are normally cleared in early 
convalescence limiting chronic liver disease. Serological tests are under development but are presently 
plagued by non-specificity problems. 
 The Delta Agent: The delta agent is normally found only in association with hepatitis B although 
it is a putative Non-A, Non-B virus. Currently delta is hypothesised as being a defective RNA virus 
relying on hepatitis B for some of its function, including possibly the ‘loan’ of HBaAg as coat material. 
 It was discovered by Dr. Mario Rizzetto in Italy, where it is more common, particularly in persons 
with repeated parenteral invasion such as drug addicts. Unfortunately work on delta is hampered by the 
lack of liver derived antigen for serological tests, so that very few laboratories indeed can work on this 
agent. 
 The Department of Medical Microbiology at U.C.D. has recently developed the first ELISA 
technique using delta antigen extracted from serum, and this will enable other laboratories to study 
various 
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populations for the delta agent and its effects. It is claimed that delta infection is found more frequently 
associated , with chronic carriers of HBsAg and those with chronic hepatitis. The cause and,’ effect 
relationship are quite unclear, and certainly not proven. 
 The Future: Prevention is better than cure and so the main thrust through policing and education 
must be the reduction and ideally the elimination of intravenous drug abuse. In the interim proper 
facilities must be made available for the management of these patients by the psychiatrist and physician 
together with the required backup haematological, biochemical, serological and immunological teams. As 
far as possible this team must be on the same site. 
 The abuser with suspected or known virus associated liver disease must be isolated and all health 
care personnel attending these patients must be offered Hepatitis B vaccine. This is probably simpler than 
testing 10 determine those who do or do not require such vaccination as screening is not without cost and 
no risk has ensued from vaccinating those with previous HBV infection. 
 It must be remembered that such vaccination will not intiluence the outcome of disease. 
Vaccinations against Non-A, Non-B viruses must also be offered when available. Until HBV vaccination 
becomes available HBIG must be available for those accidentally exposed to HBV infection. Babies of 
acutely HBV infected mothers probably do best by getting both HBIG and HB vaccine. 
 
 Treatments aimed at lessening the risk of acute hepatitis progressing to chronic hepatitis and of 
chronic active hepatitis progressing to chronic active hepatitis with cirrhosis must 
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